Neovacs SA
0.10
EUR
0.00
(0.00%)
ISIN
FR0014018EV4
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
EUR
•
in mil. unless spec.Working Capital
EUR
•
in mil. unless spec.Growth Rates
EUR
•
in mil. unless spec.Semi-annual Revenue
EUR
•
in mil. unless spec.Semi-annual Earnings Per Share
EUR
•
in mil. unless spec.Semi-annual Dividends Per Share
EUR
•
in mil. unless spec.Company Description
- CEO
- Hugo Brugière
- Full Time Employees
- 16
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 14 Rue De La Republique Suresnes France 92150
- IPO Date
- Apr 21, 2010
- Website
- neovacs.fr
- Similar Companies
- Business
- Neovacs S.A. is a French biotechnology company specializing in the research, development, and commercialization of therapeutic vaccines targeting autoimmune, inflammatory, allergy, and cancer diseases. The company primarily develops treatment candidates based on its proprietary Kinoid technology, which induces an immune response against self-antigens involved in these diseases. Its main product pipeline includes IFNα Kinoid®, an anti-interferon alpha vaccine in Phase IIb clinical trials for lupus erythematosus and Phase IIa for dermatomyositis, TNF-Kinoids, and VEGF-Kinoids targeting autoimmune conditions such as Crohn’s disease and rheumatoid arthritis, as well as other preclinical candidates aimed at allergies including asthma, dermatomyositis, and food allergies. Neovacs also focuses on the continual advancement of its Kinoid platform to meet patient needs and regulatory requirements in France, Europe, and the United States. In the last two years, Neovacs has undertaken significant operational and strategic initiatives including a €7.5 million follow-on offering to strengthen its capital base, the closing of a €250,000 convertible bond funding round in 2025, and a notable reverse stock split executed mid-2025 to improve stock liquidity and market positioning. The company has also formed key production partnerships, notably with 3P Biopharmaceuticals for the manufacturing of its interferon alpha vaccine, and maintains active collaboration with hospital research units such as Hôpital Foch in France focused on pneumology research. Furthermore, Neovacs invested €2 million to hold a 15% stake in a financial vehicle acquiring Famar Lyon, signaling a strategic expansion in production capabilities. The company operates largely within France and the United States through its subsidiary structure and maintains investments in biotech and medtech ventures to diversify its portfolio and innovation reach. Founded in 2000 and headquartered in Suresnes, France, Neovacs targets autoimmune and inflammatory disease markets, offering innovative therapeutic vaccines that represent a novel immunotherapy approach distinct from conventional treatments. Its customer base primarily includes pharmaceutical companies, healthcare providers, and research institutions involved in advanced disease treatment modalities. Neovacs continues to seek partnerships, licensing opportunities, and potential co-development deals to enhance clinical trial progress and broaden its product commercialization footprint across Europe and North America.